Chemokine Heteromers and Their Impact on Cellular Function—A Conceptual Framework
暂无分享,去创建一个
[1] M. Bianchi,et al. The acidic intrinsically disordered region of the inflammatory mediator HMGB1 mediates fuzzy interactions with chemokine CXCL12 , 2023, bioRxiv.
[2] M. Uguccioni,et al. The chemokine landscape: one system multiple shades , 2023, Frontiers in Immunology.
[3] I. Schiessl,et al. Chemokine CXCL4 interactions with extracellular matrix proteoglycans mediate widespread immune cell recruitment independent of chemokine receptors. , 2023, Cell reports.
[4] R. Lande,et al. CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells , 2022, International journal of molecular sciences.
[5] A. Gottlieb,et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) , 2022, The Lancet.
[6] B. Volkman,et al. A new obligate CXCL4–CXCL12 heterodimer for studying chemokine heterodimer activities and mechanisms , 2022, Scientific Reports.
[7] R. Koenen,et al. Galectokines: The Promiscuous Relationship between Galectins and Cytokines , 2022, Biomolecules.
[8] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[9] Y. Döring,et al. Targeting platelet-derived CXCL12 impedes arterial thrombosis. , 2022, Blood.
[10] J. Bernhagen,et al. Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation , 2021, Cellular and Molecular Life Sciences.
[11] K. Wichapong,et al. The marriage of chemokines and galectins as functional heterodimers , 2021, Cellular and Molecular Life Sciences.
[12] B. Volkman,et al. The dimeric form of CXCL12 binds to atypical chemokine receptor 1 , 2021, Science Signaling.
[13] Wing Yee Lai,et al. Latest update on chemokine receptors as therapeutic targets , 2021, Biochemical Society transactions.
[14] J. Galipeau. Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity , 2021, Stem cells.
[15] R. Koenen,et al. Chemokines modulate glycan binding and the immunoregulatory activity of galectins , 2021, Communications Biology.
[16] K. Rajarathnam,et al. Structural Basis of a Chemokine Heterodimer Binding to Glycosaminoglycans. , 2021, The Biochemical journal.
[17] R. Koenen,et al. Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro , 2021, PloS one.
[18] C. Rüegg,et al. β-Arrestin1 and β-Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4 , 2020, Frontiers in Immunology.
[19] K. Pahan,et al. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE , 2020, Proceedings of the National Academy of Sciences.
[20] S. Bhattacharya,et al. Engineered anti-inflammatory peptides inspired by mapping an evasin–chemokine interaction , 2020, The Journal of Biological Chemistry.
[21] R. Gazzinelli,et al. CCL3/Macrophage Inflammatory Protein-1α Is Dually Involved in Parasite Persistence and Induction of a TNF- and IFNγ-Enriched Inflammatory Milieu in Trypanosoma cruzi-Induced Chronic Cardiomyopathy , 2020, Frontiers in Immunology.
[22] Gary D Bader,et al. A reference map of the human binary protein interactome , 2020, Nature.
[23] O. Soehnlein,et al. Chemokines and galectins form heterodimers to modulate inflammation , 2020, EMBO reports.
[24] R. Koenen,et al. Tick Saliva Protein Evasin-3 Allows for Visualization of Inflammation in Arteries through Interactions with CXC-Type Chemokines Deposited on Activated Endothelium , 2020, Bioconjugate chemistry.
[25] J. Galipeau,et al. CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury , 2020, Cell reports.
[26] L. Rauova,et al. CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration. , 2019, Cellular signalling.
[27] R. Koenen,et al. Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2 , 2019, The Journal of Biological Chemistry.
[28] Ernest Y Lee,et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis , 2019, Nature Communications.
[29] M. Bianchi,et al. Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment , 2019, bioRxiv.
[30] A. Cavalli,et al. Oxidation State Dependent Conformational Changes of HMGB1 Regulate the Formation of the CXCL12/HMGB1 Heterocomplex , 2019, bioRxiv.
[31] M. Uguccioni,et al. Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity , 2018, Front. Immunol..
[32] B. Volkman,et al. The Solution Structure of CCL28 Reveals Structural Lability that Does Not Constrain Antifungal Activity. , 2018, Journal of molecular biology.
[33] R. Koenen,et al. Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis , 2018, Scientific Reports.
[34] J. Fox,et al. CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration , 2018, Scientific Reports.
[35] C. Billottet,et al. Oligomerization State of CXCL4 Chemokines Regulates G Protein-Coupled Receptor Activation. , 2017, ACS chemical biology.
[36] K. Rajarathnam,et al. Platelet-Derived Chemokine CXCL7 Dimer Preferentially Exists in the Glycosaminoglycan-Bound Form: Implications for Neutrophil–Platelet Crosstalk , 2017, Front. Immunol..
[37] U. Desai,et al. FIGURES FOR : Solution structure of CXCL 13 and heparan sulfate binding show that GAG binding site and cellular signalling rely on distinct domains , 2017 .
[38] A. Valente,et al. Insights into CC Chemokine Ligand 2/Chemokine Receptor 2 Molecular Recognition: A Step Forward toward Antichemotactic Agents. , 2017, Biochemistry.
[39] R. Koenen,et al. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation , 2017, Science Translational Medicine.
[40] K. Rajarathnam,et al. Chemokine CXCL7 Heterodimers: Structural Insights, CXCR2 Receptor Function, and Glycosaminoglycan Interactions , 2017, International journal of molecular sciences.
[41] K. Rajarathnam,et al. Structural Basis of Native CXCL7 Monomer Binding to CXCR2 Receptor N-Domain and Glycosaminoglycan Heparin , 2017, International journal of molecular sciences.
[42] R. Koenen,et al. Probing Functional Heteromeric Chemokine Protein–Protein Interactions through Conformation‐Assisted Oxime Ligation , 2016, Angewandte Chemie.
[43] Baohui Xu,et al. MKEY, a Peptide Inhibitor of CXCL4‐CCL5 Heterodimer Formation, Protects Against Stroke in Mice , 2016, Journal of the American Heart Association.
[44] Kai A. Kropp,et al. Chemokine binding proteins: An immunomodulatory strategy going viral. , 2016, Cytokine & growth factor reviews.
[45] A. Dinner,et al. Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3 , 2016, Proceedings of the National Academy of Sciences.
[46] D. Fremont,et al. Parallel Evolution of Chemokine Binding by Structurally Related Herpesvirus Decoy Receptors. , 2016, Structure.
[47] K. Rajarathnam,et al. CXCL1/MGSA Is a Novel Glycosaminoglycan (GAG)-binding Chemokine , 2015, The Journal of Biological Chemistry.
[48] C. Weber,et al. Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5 , 2015, Science Translational Medicine.
[49] T. Handel,et al. The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization. , 2015, Glycobiology.
[50] R. Couñago,et al. Structures of Orf Virus Chemokine Binding Protein in Complex with Host Chemokines Reveal Clues to Broad Binding Specificity. , 2015, Structure.
[51] J. Prestegard,et al. Interactions of the Chemokine CCL5/RANTES with Medium-Sized Chondroitin Sulfate Ligands. , 2015, Structure.
[52] E. García-Zepeda,et al. Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents , 2015, International journal of molecular sciences.
[53] Hualiang Jiang,et al. Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.
[54] I. Štibrániová,et al. Tick salivary compounds: their role in modulation of host defences and pathogen transmission , 2013, Front. Cell. Infect. Microbiol..
[55] M. Lotze,et al. HMGB1 in Cancer: Good, Bad, or Both? , 2013, Clinical Cancer Research.
[56] Baohui Xu,et al. Peptide Inhibitor of CXCL4–CCL5 Heterodimer Formation, MKEY, Inhibits Experimental Aortic Aneurysm Initiation and Progression , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[57] K. Rajarathnam,et al. Chemokine CXCL1 Dimer Is a Potent Agonist for the CXCR2 Receptor* , 2013, The Journal of Biological Chemistry.
[58] R. Linhardt,et al. Heparin Oligosaccharides Inhibit Chemokine (CXC Motif) Ligand 12 (CXCL12) Cardioprotection by Binding Orthogonal to the Dimerization Interface, Promoting Oligomerization, and Competing with the Chemokine (CXC Motif) Receptor 4 (CXCR4) N Terminus* , 2012, The Journal of Biological Chemistry.
[59] V. Kuchroo,et al. IL-12 family cytokines: immunological playmakers , 2012, Nature Immunology.
[60] Pascal Braun,et al. History of protein–protein interactions: From egg‐white to complex networks , 2012, Proteomics.
[61] R. Koenen,et al. Touch of Chemokines , 2012, Front. Immun..
[62] K. Preissner,et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. , 2012, American journal of respiratory and critical care medicine.
[63] L. Varani,et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 , 2012, The Journal of experimental medicine.
[64] A. Christopoulos,et al. Design and Receptor Interactions of Obligate Dimeric Mutant of Chemokine Monocyte Chemoattractant Protein-1 (MCP-1)* , 2012, The Journal of Biological Chemistry.
[65] S. Takayama,et al. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. , 2012, The Biochemical journal.
[66] Wuyuan Lu,et al. α‐Defensins in human innate immunity , 2012, Immunological reviews.
[67] T. Nevell,et al. A copper-hydrogen peroxide redox system induces dityrosine cross-links and chemokine oligomerisation. , 2011, Cytokine.
[68] N. Heveker,et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways , 2011, Proceedings of the National Academy of Sciences.
[69] J. Prestegard,et al. Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. , 2011, Structure.
[70] R. Koenen,et al. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment , 2011, Journal of thrombosis and haemostasis : JTH.
[71] R. Koenen,et al. Polymerization of MIP‐1 chemokine (CCL3 and CCL4) and clearance of MIP‐1 by insulin‐degrading enzyme , 2010, The EMBO journal.
[72] C. Doglioni,et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T‐cell infiltration and positioning of malignant B cells , 2010, International journal of cancer.
[73] Ariane L. Jansma,et al. Characterization of the Chemokine CXCL11-Heparin Interaction Suggests Two Different Affinities for Glycosaminoglycans* , 2010, The Journal of Biological Chemistry.
[74] Y. Xiong,et al. Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family , 2010, Proteins.
[75] Ariane L. Jansma,et al. NMR Analysis of the Structure, Dynamics, and Unique Oligomerization Properties of the Chemokine CCL27* , 2010, The Journal of Biological Chemistry.
[76] J. Shaw,et al. Structural Basis of Chemokine Sequestration by a Tick Chemokine Binding Protein: The Crystal Structure of the Complex between Evasin-1 and CCL3 , 2009, PloS one.
[77] M. Bianchi,et al. HMGB1 loves company , 2009, Journal of leukocyte biology.
[78] K. Rajarathnam,et al. Differential Activation and Regulation of CXCR1 and CXCR2 by CXCL8 Monomer and Dimer1 , 2009, The Journal of Immunology.
[79] C. Weber,et al. The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function. , 2009, Molecular immunology.
[80] M. Shoham,et al. Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. , 2009, New biotechnology.
[81] M. Locati,et al. Synergy‐inducing chemokines enhance CCR2 ligand activities on monocytes , 2009, European journal of immunology.
[82] Christoph Seibert,et al. Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.
[83] Y. Sham,et al. CXC and CC Chemokines Form Mixed Heterodimers , 2008, Journal of Biological Chemistry.
[84] Osamu Yoshie,et al. Extensive expansion and diversification of the chemokine gene family in zebrafish: Identification of a novel chemokine subfamily CX , 2008, BMC Genomics.
[85] Brian F. Volkman,et al. Interconversion between two unrelated protein folds in the lymphotactin native state , 2008, Proceedings of the National Academy of Sciences.
[86] L. Fouser,et al. An IL-17F/A Heterodimer Protein Is Produced by Mouse Th17 Cells and Induces Airway Neutrophil Recruitment , 2007, The Journal of Immunology.
[87] Hongjun Jin,et al. The Human CC Chemokine MIP-1β Dimer Is Not Competent to Bind to the CCR5 Receptor* , 2007, Journal of Biological Chemistry.
[88] C. Weber,et al. Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease , 2007, Circulation research.
[89] T. Handel,et al. Heterodimerization of CCR2 Chemokines and Regulation by Glycosaminoglycan Binding* , 2006, Journal of Biological Chemistry.
[90] A. Proudfoot,et al. The biological relevance of chemokine-proteoglycan interactions. , 2006, Biochemical Society transactions.
[91] Silvia Sebastiani,et al. A rich chemokine environment strongly enhances leukocyte migration and activities. , 2005, Blood.
[92] M. Uguccioni,et al. CCL22‐induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first β‐strand of chemokine , 2005, European journal of immunology.
[93] Guoping Wu,et al. Platelet Factor 4 and Interleukin-8 CXC Chemokine Heterodimer Formation Modulates Function at the Quaternary Structural Level* , 2005, Journal of Biological Chemistry.
[94] Christopher Chin,et al. Dimer Dissociation Is Essential for Interleukin-8 (IL-8) Binding to CXCR1 Receptor* , 2004, Journal of Biological Chemistry.
[95] Yusuke Nakamura,et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro , 2004, Nature.
[96] F. Petersen,et al. Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases, whereas PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. , 2004, Blood.
[97] F. Mach,et al. Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.
[98] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[99] Arkadiusz Z Dudek,et al. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. , 2003, Blood.
[100] A. Imberty,et al. A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization. , 2002, Biochemistry.
[101] M. Farzan,et al. The Role of Post-translational Modifications of the CXCR4 Amino Terminus in Stromal-derived Factor 1α Association and HIV-1 Entry* , 2002, The Journal of Biological Chemistry.
[102] J. Markley,et al. Monomeric solution structure of the prototypical 'C' chemokine lymphotactin. , 2001, Biochemistry.
[103] M. Norcross,et al. Identification of Human Macrophage Inflammatory Proteins 1α and 1β as a Native Secreted Heterodimer* , 2001, The Journal of Biological Chemistry.
[104] A. Trkola,et al. The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity* , 2001, The Journal of Biological Chemistry.
[105] K. Ley,et al. RANTES Deposition by Platelets Triggers Monocyte Arrest on Inflamed and Atherosclerotic Endothelium , 2001, Circulation.
[106] P. Roey,et al. Three-dimensional structure of human follicle-stimulating hormone. , 2001, Molecular endocrinology.
[107] D. Spillmann,et al. Characterization of a Neutrophil Cell Surface Glycosaminoglycan That Mediates Binding of Platelet Factor 4* , 1999, The Journal of Biological Chemistry.
[108] K. Jarnagin,et al. Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B* , 1998, The Journal of Biological Chemistry.
[109] H. Flad,et al. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. , 1998, Journal of immunology.
[110] D. Spillmann,et al. Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.
[111] B D Sykes,et al. 1H NMR solution structure of an active monomeric interleukin-8. , 1995, Biochemistry.
[112] K. Mayo,et al. Subunit association and structural analysis of platelet basic protein and related proteins investigated by 1H NMR spectroscopy and circular dichroism. , 1994, The Journal of biological chemistry.
[113] L. Chen,et al. Crystal structure of recombinant human platelet factor 4. , 1994, Biochemistry.
[114] B. Sykes,et al. Neutrophil activation by monomeric interleukin-8 , 1994 .
[115] A. Zernecke,et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice , 2009, Nature Medicine.
[116] B. Volkman,et al. Chapter 3. Lymphotactin structural dynamics. , 2009, Methods in enzymology.
[117] Christian Weber,et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. , 2005, Blood.
[118] Elias Lolis,et al. Structure, function, and inhibition of chemokines. , 2002, Annual review of pharmacology and toxicology.
[119] J. Lubkowski,et al. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions , 1997, Nature Structural Biology.